{"transactions":[{"id":1509238,"issuer":{"id":7454,"kind":"organization","name":"BriaCell Therapeutics Corp."},"owners":[{"id":90829,"kind":"person","name":"Lustig Marc","position":1,"cik":"0001940908","reported_name":"Lustig Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Warrants","published_at":"2024-05-20T16:00:14.000Z","date":"2024-05-14","kind":"purchase","planned":false,"acquired":true,"shares":902935,"ownership":{"direct":false,"nature":"By L5 Capital Inc."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer."}],"balance_after":902935,"derivative":{"exercise_price":2.11,"underlying":"Common Stock","underlying_shares":902935},"source":{"system":"sec-edgar","filing":"0001493152-24-020660","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1940908/000149315224020660/ownership.xml","form_type":"4"}},{"id":1509237,"issuer":{"id":7454,"kind":"organization","name":"BriaCell Therapeutics Corp."},"owners":[{"id":90829,"kind":"person","name":"Lustig Marc","position":1,"cik":"0001940908","reported_name":"Lustig Marc","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2024-05-20T16:00:14.000Z","date":"2024-05-14","kind":"purchase","planned":false,"acquired":true,"shares":902935,"price":2.215,"value":2000001.025,"ownership":{"direct":false,"nature":"By L5 Capital Inc."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The common shares and warrants reported on this Form 4 were purchased by L5 Capital Inc. in an offering at a combined purchase price of $2.215 per common share and accompanying warrant, for an aggregate purchase price of $2,000,000 pursuant to a securities purchase agreement dated May 14, 2024. The warrants will be exercisable six months from the date of issuance at an exercise price of $2.11 and will expire on the five year anniversary of the initial exercise date. L5 Capital Inc. is controlled by the Reporting Person, Marc Lustig, a director of the Issuer."}],"balance_after":2542935,"source":{"system":"sec-edgar","filing":"0001493152-24-020660","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1940908/000149315224020660/ownership.xml","form_type":"4"}},{"id":2075511,"issuer":{"id":7454,"kind":"organization","name":"BriaCell Therapeutics Corp."},"owners":[{"id":121279,"kind":"person","name":"Bondarenko Jamieson","position":1,"cik":"0001942516","reported_name":"Bondarenko Jamieson","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman"}}],"security":"Common Shares","published_at":"2022-12-28T21:38:08.000Z","date":"2022-12-28","kind":"purchase","acquired":true,"shares":28000,"price":4.58,"value":128240.0,"ownership":{"direct":true},"balance_after":169856,"source":{"system":"sec-edgar","filing":"0001493152-22-036669","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315222036669/ownership.xml","form_type":"4"}},{"id":2075510,"issuer":{"id":7454,"kind":"organization","name":"BriaCell Therapeutics Corp."},"owners":[{"id":121278,"kind":"person","name":"Williams William V.","position":1,"cik":"0001939302","reported_name":"Williams William V.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, CEO"}}],"security":"Warrant","published_at":"2022-12-28T20:22:52.000Z","date":"2022-12-23","kind":"purchase","acquired":true,"shares":2530,"price":1.94,"value":4908.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 8 is a weighted average price. These Warrants were purchased in multiple transactions at prices ranging from $1.97 to $2.00 per Warrant, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Warrants purchased at each separate price within the ranges set forth herein."}],"balance_after":29802,"derivative":{"exercise_price":5.3125,"exercise_date":"2021-02-26","expiration_date":"2026-02-25","underlying":"Common Shares","underlying_shares":2530},"source":{"system":"sec-edgar","filing":"0001493152-22-036643","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315222036643/ownership.xml","form_type":"4"}},{"id":2079783,"issuer":{"id":7454,"kind":"organization","name":"BriaCell Therapeutics Corp."},"owners":[{"id":121279,"kind":"person","name":"Bondarenko Jamieson","position":1,"cik":"0001942516","reported_name":"Bondarenko Jamieson","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2022-12-21T02:02:35.000Z","date":"2022-12-20","kind":"purchase","acquired":true,"shares":22000,"price":5.35,"value":117700.0,"ownership":{"direct":true},"balance_after":141856,"source":{"system":"sec-edgar","filing":"0001493152-22-036060","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315222036060/ownership.xml","form_type":"4"}}]}